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Novel gallium(III) complexes transported by MDR1
P-glycoprotein: potential PET imaging agents for probing
P-glycoprotein-mediated transport activity in vivo
V Sharma1, A Beatty2, S-P Wey3, J Dahlheimer1, CM Pica1, CL Crankshaw1,
L Bass1, MA Green3, MJ Welch1 and D Piwnica-Worms1
Background: Multidrug resistance (MDR) mediated by expression of MDR1
P-glycoprotein (Pgp) represents one of the best characterized barriers to
chemotherapy in cancer patients. Positron emission tomography (PET)
agents for analysis of Pgp-mediated drug transport activity in vivo would
enable noninvasive assessment of chemotherapeutic regimens and MDR
gene therapy. 
Results: Candidate Schiff-base phenolic gallium(III) complexes were
synthesized from their heptadentate precursors and gallium(III)acetylacetonate.
Crystal structures demonstrated a hexacoordinated central gallium with overall
trans-pseudo-octahedral geometry. Radiolabeled 67Ga-complexes were
obtained in high purity and screened in drug-sensitive (Pgp–) and MDR (Pgp+)
tumor cells. Compared with control, lead compound 6 demonstrated
antagonist-reversible 55-fold lower accumulation in Pgp-expressing MDR cells.
Furthermore, compared with wild-type control, quantitative pharmacokinetic
analysis showed markedly increased penetration and retention of 6 in brain and
liver tissues of mdr1a/b(–/–) gene disrupted mice, correctly mapping
Pgp-mediated transport activity at the capillary blood–brain barrier and
hepatocellular biliary cannalicular surface in vivo. 
Conclusions: These results indicate that gallium(III) complex 6 is recognized by
MDR1 Pgp as an avid transport substrate, thereby providing a useful scaffold to
generate 68Ga radiopharmaceuticals for molecular imaging of Pgp transport
activity in tumors and tissues in vivo using PET.
Introduction
Resistance of malignant tumors to chemotherapeutic
agents is a major cause of treatment failure in patients with
cancer [1,2]. One resistance phenotype, known as mul-
tidrug resistance (MDR), is characterized by the failure to
respond to a variety of structurally and functionally diverse
natural product cytotoxic and xenobiotic agents. MDR1
P-glycoprotein (Pgp), a 140–180 kDa plasma membrane
transporter [3,4], is one of the best characterized mediators
of multidrug resistance and is reported to alter the mem-
brane permeability to cytotoxic compounds and/or
enhance the efflux of these agents out of cancer cells [1,2].
Identification a priori of the molecular target of a given
therapeutic regimen, such as Pgp, is becoming increasingly
common to select patients most likely to benefit from a
given therapy. In addition, transgenic expression of the
MDR1 gene has been explored for hematopoietic cell pro-
tection in the context of cancer chemotherapy [5–7]
wherein Pgp could protect hematopoietic progenitor cells
from chemotherapy-induced myelotoxicity. Indeed,
hematopoietic cells transduced via retroviral-mediated
transfer of the MDR1 gene have shown preferential sur-
vival after treatment of the animal with MDR drugs [7].
Methods to interrogate Pgp transport activity have there-
fore been sought [8]. In this regard, various single photon
emission computed tomography (SPECT) radiopharma-
ceuticals exemplified by 99mTc-Sestamibi [9], 99mTcQ-58
[10], 99mTc-Tetrofosmin [11–13] and 99mTc-Furifosmin
[12,14] have been validated as transport substrates for
MDR1 Pgp, enabling noninvasive imaging of Pgp-medi-
ated transport activity in vivo. To exploit the greater sen-
sitivity and quantification capabilities of positron
emission tomography (PET), however, radiopharmaceuti-
cals of short half-life isotopes are desired. Based on struc-
tures of known MDR cytotoxic drugs or classic
modulators, several 11C-labeled PET agents [15–17] or
potentially 11C-labeled compounds [18,19] targeting Pgp
have been reported. Although promising preliminary data
have been generated, the agents suffer from modest
radiochemical yields and complex pharmacokinetics
in vivo mediated, at least in part, by rapid metabolism of
the radiolabeled compounds. 
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We sought an alternative strategy focused on discovering a
nonmetabolized Pgp-targeted PET agent. Schiff-base
ligands [20–22] and amine phenol ligands [23,24] possess-
ing an N4O2 donor core are well known. Gallium(III) com-
plexes of selected Schiff-base ligands show potential as
positron-emitting radiopharmaceuticals for use in myocar-
dial perfusion imaging [25–28]. In addition, various stable
Ga(III) complexes of this class of Schiff-base phenolic
ligands also possess cytotoxic activity against tumor cells
which is modified by expression of MDR1 Pgp [29], sug-
gesting that the compounds might be recognized as trans-
port substrates of Pgp. Here we report the synthesis,
characterization, and crystal structures of the two most
favorable Pgp-targeted Ga(III) complexes, (bis(3-ethoxy-
2-hydroxy-benzylidene)-N,N′-bis(2,2-dimethyl-3-amino-
propyl)ethylenediamine)-gallium(III) perchlorate (6) and
(bis(5-ethoxy-2-hydroxy-benzylidene)-N,N′-bis(2,2-di-
methyl-3-aminopropyl)ethylenediamine)-gallium(III)
iodide (7), along with tumor cell transport profiles and
murine biodistributions indicating the potential for PET
imaging of MDR1 Pgp-mediated transport activity in vivo.
Results and discussion
Chemistry
Compounds 6 and 7 were synthesized as shown in
Figure 1. Bis(N,N′-amino-2,2-dimethylpropane)ethylene-
diamine 1 was obtained by reacting dibromoethane and
2,2-dimethylpropane-1,3-diamine at room temperature.
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Figure 1
Synthetic scheme for Ga(III) complexes of
hexadentate bis(salicylaldimine) ligands,
where R3 = OEt, R5 = H for 3-ethoxy-
ENBDMPI (6) or R3 = H, R5 = OEt for
5-ethoxy-ENBDMPI (7) derived from their
precursor ligands, H33-Eabi (4) or H35-Eabi
(5), respectively.
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2-Hydroxy-3-ethoxy-benzaldehyde (2) was commercially
available. However, 2-hydroxy-5-ethoxy-benzaldehyde (3)
was obtained through a reaction involving 4-ethoxyphenol
and paraformaldehyde using 10–20% tin(IV) chloride and
trioctylamine in toluene [30]. The heptadentate precur-
sors H33-Eabi (4; 2-(2-hydroxy-3-ethoxyphenyl)-1,3-bis[4-
aza-5-(2′-hydroxy-3′-ethoxyphenyl)2′′,2′′′-dimethyl-but-4′
-ene-1′-yl]-1,3-imidazolidine) and H35-Eabi (5; 2-(2-
hydroxy-5-ethoxyphenyl)-1,3-bis[4-aza-5-(2′-hydroxy-5′-
ethoxyphenyl)2′′,2′′′-dimethyl-but-4′-ene-1′-yl]-1,3-imida
zolidine). were obtained through condensation of com-
pounds 2 or 3 and 1 in appropriate molar ratios using proce-
dures described previously (Figure 1) [27,29]. The presence
of resonance signals at 3.78 and 3.70 ppm in the 1H NMR
spectra and 91.3 and 91.8 ppm in the proton decoupled 13C
NMR of 4 and 5, assigned to benzylic protons and carbons,
respectively, suggested formation of the expected five-
membered imidazolidine rings. Furthermore, proton decou-
pled 13C NMR of 4 and 5 recorded in CDCl3 at room
temperature demonstrated 24 resonance signals supporting
formation of the desired precursors. On treatment of pre-
cursors 4 and 5 with gallium(III)acetylacetonate in ethanol,
cleavage of the imidazolidine ring took place leading to for-
mation of metal complexes. The aldimino protons were
shifted downfield compared with the precursors and
appeared at 8.19 and 8.14 ppm in 6 and 7, respectively, sug-
gesting the coordination of the imine with the central
gallium atom. Furthermore, the appearance of slightly
broad singlets assigned to amine protons at 4.90 and
4.82 ppm in 6 and 7, respectively, were indicative of cleav-
age of the imidazolidine ring, thereby providing secondary
amine nitrogens for coordination with the central metal
core. Furthermore, although the cleaved precursors yield
achiral and flexible free ligands, these ligands form rigid
complexes upon coordination with Ga(III) (Figure 1), as
evident from the series of multiplets in the hydrocarbon
region. We ascribe these multiplets to chirality of the coor-
dinated amine nitrogens. Furthermore, the chemical shifts
of aldimino and amine protons, including a series of over-
lapping signals resulting from the hydrocarbon backbone,
are in accord with earlier reported gallium complexes
[26,27,29]. The presence of a single set of signals due to
aromatic rings and aldimino protons in 1H NMR spectra
combined with 15 resonance signals in 13C NMR spectra for
6 and 7 suggest the structure is symmetrical in solution [29]. 
Crystals suitable for X-ray crystallography were grown by
slow diffusion of ether in methanol over 3–4 days and slow
evaporation of methanol at room temperature for 6 and 7,
respectively. The Oak Ridge Thermal Ellipsoid Plot
(ORTEP) drawings of 6 and 7 are shown in Figures 2
and 3, respectively, along with selected bond angles and
interatomic distances. The crystal structure provided
direct evidence that gallium is coordinated symmetrically
and simultaneously to the N4O2 donor core of the
ligand. The structure revealed that the central gallium is 
hexacoordinated involving two phenoxy oxygens (O1 and
O2), two secondary amine nitrogens (N2 and N3) and two
imine nitrogens (N1 and N4) with overall trans-pseudooc-
tahedral geometry. Compared with the closest gallium(III)
structural analog [27], the interatomic distances of the Ga-
O or Ga-N involved in the coordination sphere are similar
and suggest comparable stability of the complexes. In
addition, radio-thin layer chromatography (TLC) analysis
of 67Ga-labeled complexes 6 and 7 stored in saline:ethanol
(90:10) for up to four days demonstrated only parent com-
pound, further documenting stability of the complexes
under aqueous conditions. As with the previously reported
gallium(III) complex [27], trans angles involving O(1)-Ga-
O(2) are close to linear. However, trans angles involving
nitrogens exemplified by N(4)-Ga-N(2) and N(3)-Ga-N(1)
(Figure 2) are 170.5(1)° and 168.1(1)°, respectively, and are
~2° more acute than the previously published gallium(III)
complex. Similarly, cis angles involving O-Ga-N are in close
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Figure 2
ORTEP drawing of [(3-ethoxy-ENBDMPI)Ga]+ (6) cation in [(3-ethoxy-
ENBDMPI)Ga]ClO4 showing the crystallographic numbering scheme.
Atoms are represented by thermal ellipsoids corresponding to 20%
probability. Structural parameters: pale yellow crystal, monoclinic, P21/c;
a = 8.700(3) Å, b = 17.396(2) Å, c = 22.750(2) Å, β = 93.39(2)°;
V = 3437.2(13) Å3; Z = 4; R1 [I > 2σ(I)] = 0.0413; GOF = 1.058.
Selected bond angles and interatomic distances: bond angles (deg),
N1-Ga-N2, 86.73 (12); N2-Ga-N3, 84.08 (12); N3-Ga-N4, 87.90 (12);
N4-Ga-N1, 101.85 (12); O1-Ga-O2, 179.02 (11); N1-Ga-N3, 168.13
(12); N2-Ga-N4, 170.52 (12); O1-Ga-N1, 87.26 (11); O1-Ga-N4,
91.87 (11); O2-Ga-N2, 87.75 (11); O2-Ga-N3, 93.45 (11); C1-O1-Ga,
125.6 (2); C22-O2-Ga, 124.1 (2); distances (Å), Ga-O1, 1.933(2); Ga-
O2, 1.923 (2); Ga-N1, 2.056 (3); Ga-N2, 2.091 (3); Ga-N3, 2.104 (3);
Ga-N4, 2.053 (3); O1-C1, 1.318 (4); O2-C22, 1.322 (4).
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agreement to values observed previously [27,31], suggest-
ing a mildly distorted octahedral geometry around the
gallium. The smallest angle N2-Ga-N3 can be attributed to
the restrictions of the five-membered chelate ring involving
N(2), C(11), C(12), N(3) and Ga. In comparison with the
3-ethoxy substituted compound 6 (Figure 2), the 5-ethoxy
analog 7 (Figure 3) was highly similar in its distances and
angles around the coordination sphere. However, C1-O1-
Ga and C22-O2-Ga are 123.4(3)° and 122.0(2)°, respec-
tively, and are 2° more acute in 7 compared to 6, suggesting
slight variation in the positions of the peripheral con-
stituents of each molecule, including the aromatic rings.
Cell transport assays
Radiolabeled 67Ga complexes were obtained via 67Ga(acety-
lacetonate)3 and precursors 4 and 5 in ethanol at 80°C for
30 min using published procedures [27]. Final reaction mix-
tures were passed through nylon syringe filters (0.2 µm) and
silica to remove excess ligand. Synthesis and workup could
be accomplished in less than an hour, an interval of signifi-
cant practical value for potential PET radiopharmaceuticals
labeled with 68Ga (t1/2 = 68 min), which is obtained from
commercially available 68Ge (t1/2 = 271d) generators. Com-
pounds were assessed for their radiopharmaceutical purity
by radio-TLC [methanol:saline, 90:10; Rf:0.47(6), 0.48(7)]
and found to be > 95% pure. 
67Ga(III) complexes were evaluated for their MDR1 Pgp-
mediated transport activity in a whole-cell transport
assay using drug-sensitive human epidermal carcinoma
KB-3-1 cells and the colchicine-selected MDR derivative
KB-8-5 cells as described previously [12,32]. KB-3-1 cells
do not express Pgp, whereas KB-8-5 cells express modest
levels of Pgp as documented by Western blot analysis
with mAb C219 [10]. Net cell content of many hydropho-
bic cationic tracers transported by Pgp is a function of
both passive potential-dependent influx and transporter-
mediated efflux [33]. Accordingly, favorable cationic
67Ga complexes should highly penetrate KB-3-1 cells as
result of the inwardly directed electrochemical driving
forces [32]. As a further test of membrane potential-
dependent influx, incubation of KB-3-1 cells in 120 mm
K+/20 mM Cl– buffer containing the potassium ionophore
valinomycin (1 µg/ml) has been shown to collapse mito-
chondrial and plasma membrane-potentials toward zero,
and reduce net tracer uptake of membrane potential-
responsive hydrophobic cations [9,34]. Net accumulation
of the 67Ga complexes should, therefore, be reduced in
high K+/valinomycin buffer, and furthermore, tracer
levels greater than that expected from equilibrium distri-
bution into the water spaces under these conditions
provide one measure of nonspecific adsorption to
hydrophobic compartments within the cells [9]. Con-
versely, MDR1-Pgp-mediated outward transport of candi-
date 67Ga complexes would be expected to decrease net
cellular accumulation in KB-8-5 cells compared with KB-
3-1 cells. In addition, the potent MDR1 Pgp antagonist
GF120918 [33,35] should enhance tracer accumulation in
KB-8-5 cells by inhibiting the outward transport function
of Pgp. Desirable MDR1 targeted complexes would
therefore have the following properties: low nonspecific
binding to membranes and hydrophobic compartments
of cells; high distinction in net uptake levels between
drug-sensitive cells and MDR cells; and significant
enhancement of uptake in MDR cells upon addition of
an MDR antagonist [12].
In drug-sensitive KB-3-1 cells, the 3-ethoxy-substituted
67Ga-complex 6 demonstrated plateau accumulation of
410 ± 28 fmol (mg protein)–1 (nMo)–1 (n = 4), 55-fold
greater than drug-resistant KB-8-5 cells (Figure 4a). This
was similar to the 48-fold difference (Figure 4c) observed
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Figure 3
ORTEP drawing of [(5-ethoxy-ENBDMPI)Ga]+ (7) cation in [(5-ethoxy-
ENBDMPI)Ga]I showing the crystallographic numbering scheme. Atoms
are represented by thermal ellipsoids corresponding to 20% probability.
Structural parameters: pale yellow crystal, monoclinic, P21/c;
a = 8.0987(8) Å, b = 20.394(2) Å, c = 20.603(2) Å; β = 95.239(8)°;
V = 3388.7(6) Å3; Z = 4; R1 [I > 2σ(I)] = 0.0333; GOF = 1.136.
Selected bond angles and interatomic distances: bond angles (deg),
N1-Ga-N2, 87.07 (13); N2-Ga-N3, 83.26 (13); N3-Ga-N4, 87.65
(13); N4-Ga-N1, 102.43 (13); O1-Ga-O2, 178.89(12); N1-Ga-N3,
168.58 (13); N2-Ga-N4, 169.84 (13); O1-Ga-N1, 87.20 (12); O1-Ga-
N4, 91.54 (12); O2-Ga-N2, 88.56 (13); O2-Ga-N3, 92.86 (12); C1-
O1-Ga, 123.4 (3); C22-O2-Ga, 122.0 (2); distances (Å), Ga-O1, 1.926
(3); Ga-O2, 1.924(3); Ga-N1, 2.066 (3); Ga-N2, 2.089 (3); Ga-N3,
2.126 (3); Ga-N4, 2.066 (3); O1-C1, 1.330 (5); O2-C22, 1.333 (5).
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with 99mTc-Sestamibi (Cardiolite, hexakis(2-methoxy-
isobutylisonitrile)technetium(I) chloride), a previously
validated agent tested under identical conditions [12], and
indicated that 6 was an avid transport substrate recognized
by human MDR1 Pgp. In KB-3-1 cells, accumulation of 6
was 4.5-fold greater in control buffer than in the presence
of high K+/valinomycin buffer, consistent with a signifi-
cant response to depolarization of membrane potential.
The final cell accumulation value was 91.2 ± 7.9 fmol (mg
protein)–1 (nMo)–1 (n = 4), greater than the value expected
based on the cell water space estimated for these cells
(5.4 µl/mg protein [12]) implying a significant level of non-
specific adsorption of the complex to hydrophobic compo-
nents within the cells. Addition of GF120918 at a
concentration known to maximally inhibit Pgp (300 nM
[10]) enhanced cellular accumulation of 6 in MDR cells
towards that observed in drug-sensitive cells, again consis-
tent with a favorable transport profile. 
Using the same techniques, we also radiolabeled the
3-methoxy analog 8 and the 4,6-dimethoxy analog 9 of the
non-substituted hydrocarbon backbone ligands (Figure 5)
[29]. In comparison to 6, the drug-sensitive/drug-resistant
cell uptake ratios were significantly less for these Ga(III)
complexes (30 min cell uptake [fmol (mg protein)–1
(nMo)–1] in KB-3-1 cells, in KB-8-5 cells, and KB-3-1/
KB-8-5 ratio: 8, 47 ± 5, 17 ± 1, 2.8; 9, 252 ± 20, 42 ± 2, 6.0).
Thus the methyl substitutions in the hydrocarbon back-
bone coupled with the ethoxy functionality of 6 signifi-
cantly improved the transport profile of the complex.
Variation in the position of the ethoxy group to the 5 posi-
tion on the aromatic ring resulted in a less robust Pgp-
mediated transport profile, however (Figure 4b). The
5-ethoxy-substituted 67Ga-complex 7 showed only a
23-fold greater accumulation in drug-sensitive KB-3-1 cells
compared with KB-8-5 cells, and furthermore, addition of
GF120918 to drug-resistant KB-8-5 cells enhanced accu-
mulation of 7 to a lesser degree. Of note, 7 showed a similar
response as 6 to high K+/valinomycin buffer, suggesting a
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Figure 5
Structures of [(3-methoxy-ENBPI)67Ga]+ (8) and [(4,6-dimethoxy-
ENBPI)67Ga]+ (9).
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Figure 4
Characterization of (a) [(3-ethoxy-ENBDMPI)67Ga]+ (6), (b) [(5-ethoxy-
ENBDMPI)67Ga]+ (7) and (c) 99mTc-Sestamibi accumulation in KB-3-1
cells (left-hand columns) and MDR KB-8-5 cells (right-hand columns)
as indicated. Shown is net uptake at 30 min [fmol/(mg protein⋅nMo)]
using control buffer (black bars), 130 mM K+/valinomycin buffer (open
bars), and control buffer containing the MDR modulator GF120918
(300 nM; gray bars). Each bar represents the mean of four
determinations; line above the bar denotes ± SEM.
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similar level of lipid partitioning. The greater octanol/water
partitioning coefficient for the 3-ethoxy analog 6, for
example, compared with Tc-Sestamibi (logP = 1.7 versus
logP = 1.1, respectively), would be consistent with the
enhanced potential-independent cell accumulation (mem-
brane absorption) seen with the 67Ga complexes.
Biodistribution studies in mdr1a/b(–/–) mice
To demonstrate the potential use of radiolabeled Ga com-
plexes as imaging markers of Pgp-mediated transport
in vivo, we performed quantitative pharmacokinetic analysis
in mice following intravenous injection of the tracer. Mice
have two isoforms of Pgp (mdr1a and mdr1b) which confer
multidrug resistance [36]. The drug-transporting mdr1a Pgp
isoform is expressed in capillary endothelial cells of the
brain wherein the protein is a major component of the
blood–brain barrier [37]. Here, Pgp limits entry of a variety
of amphipathic compounds into the central nervous system
[36]. Drug-transporting Pgp isoforms are also expressed
along the biliary cannalicular surface of hepatocytes wherein
the transporters function to secrete substrates into the bile
[36]. In this regard, mdr1a/1b(–/–) gene-disrupted mice,
which have no drug-transporting Pgp, are a robust model for
evaluation of candidate MDR agents by interrogating net
tracer accumulation into brain and liver tissues [10]. 
Thus, we analyzed initial tissue uptake and retention of
67Ga-complex 6 in mdr1a/1b(–/–) mice in comparison to
wild-type FVB mice (Figure 6). Relative to wild-type
mice, mdr1a/1b(–/–) mice showed tenfold more 67Ga-
complex 6 in brain parenchyma 5 minutes after injection
of the complex (Figure 6b). Additionally, the area under
the curve from 5–120 minutes (AUC5–120) of 6 in
mdr1a/1b(–/–) brain was 62.5 ± 16.1 µCi (injected µCi)–1
(g tissue)–1 × 100 × min (n = 8), a value 17-fold greater
than wild-type mice (p < 0.005). By contrast, blood reten-
tion of 6 in mdr1a/1b(–/–) mice was 29.4 ± 8.7 µCi (injected
µCi)–1 (g tissue)–1 × 100 × min, only 1.2-fold that of wild-
type control (p > 0.5; Figure 6a). Because blood flow to the
brain does not differ between mdr1 gene disrupted and
wild-type mice [38], the marked enhancement in initial
penetration and retention of 6 in brain tissue of
mdr1a/1b(–/–) mice cannot be attributed to differences in
cerebral perfusion. Pilot imaging experiments using planar
scintigraphy also demonstrated increased visualization of
67Ga-complex 6 in the brains of mdr1a/1b(–/–) mice, com-
pared to control (data not shown), thus showing promise
for eventual quantitative imaging by clinical or microPET
[39]. Furthermore, 6 shows 3–5-fold greater differences in
brain AUC5–120 between wild-type and mdr1(–/–) mice than
99mTc-Sestamibi [40], 99mTcQ-58 [10] and 99mTc-Tetro-
fosmin [13], further documenting its potential superiority
for imaging Pgp activity in vivo.
In liver, initial accumulation of 6 was comparable between
mdr1a/1b(–/–) and wild-type mice (Figure 6c). However,
liver clearance was markedly delayed in mdr1a/1b(–/–) mice
consistent with blockade of Pgp-mediated biliary secre-
tion of the tracer. The AUC5–120 of 6 in liver tissue of
mdr1a/1b(–/–) mice was 2465 ± 440 µCi (injected µCi)–1 (g
tissue)–1 × 100 × min, twofold greater than wild-type mice.
These data further validate 67Ga-complex 6 as a substrate
for Pgp in vivo and show its potential as a molecular
imaging probe of transporter function and inhibition in the
living organism. 
Significance
One of the best characterized barriers to chemotherapy
in cancer patients is multidrug resistance (MDR) medi-
ated by expression of the MDR1 P-glycoprotein (Pgp).
We wanted to develop agents for use in positron emis-
sion tomography (PET) to allow noninvasive assess-
ment of chemotherapy regimens and MDR gene
therapy. Selected Schiff-base phenolic complexes of
Ga(III) are shown to be probes of MDR1 Pgp-mediated
transport activity. Variation in the position of the ethoxy
group from para to ortho with respect to the Ga-O-C
bond increased MDR1 Pgp recognition in vitro, suggest-
ing that the unique MDR1 Pgp transport properties of
the 3-ethoxy Ga(III)-complex 6 lie in the spatial orienta-
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Figure 6
Pharmacokinetics of [(3-ethoxy-
ENBDMPI)67Ga]+ (6) in (a) blood, (b) brain
and (c) liver of FVB mice. Wild-type (l) and
mdr1a/1b(–/–) mice (l) were administered 6
by bolus injection into a lateral tail vein and
organs harvested at the indicated times for
analysis. Data are expressed as percent of
injected dose of radioactivity per gram tissue
at each respective time point. Data points
represent the mean of 2–4 determinations
each; error bars represent ± SEM when larger
than the symbol.
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tion of the peripheral constituents of the molecule rather
than within the inner coordination sphere. Biodistribu-
tion analysis demonstrated that differences in Pgp trans-
port activity could be readily detected with tracer
concentrations of 67Ga-labeled 6 in mdr1a/1b (–/–) gene-
disrupted mice compared to control, and, therefore, 68Ga
analogs of 6 may provide useful scaffolds to generate a
PET radiopharmaceutical for quantifying the functional
status of Pgp in tumors and tissues in vivo.
Materials and methods
General methods
1,2-dibromoethane, 2,2-dimethylpropane-1,3-diamine, 3-ethoxysalicy-
aldehyde and 2 were obtained from Aldrich Chemical Co. Ga(III)acety-
lacetonate was purchased from Mathey-Johnson/Alfa Chemical Co. 1H
and 13C NMR spectra were recorded on a VARIAN 300 MHz spec-
trometer; chemical shifts are reported in δ (ppm) with reference to
TMS. Mass spectra were obtained from the Washington University
Resource for Biomedical and Bioorganic Mass Spectrometry with 3-
nitrobenzyl alcohol as a matrix. Molar conductance (κ, Ω–1mol–1cm2)
was determined with a portable conductivity meter (Orion Research,
model 120) at 25°C in acetonitrile with 0.37 mM solutions of each
complex. Octanol/water partition coefficients (P ) were determined with
radiolabeled compounds using standard methods. Elemental analyses
(C, H, N) were performed by Galbraith Laboratories, Knoxville, TN. Syn-
thesis of the radiolabeled compound 99mTc-Sestamibi was performed
with a one-step kit formulation (CardioliteTM, E. I. Du Pont, Medical
Products Division, Billerica, MA) [32].
Bis(N,N′-amino-2,2-dimethylpropane)ethylenediamine (1)
Potassium hydroxide (4.0 g, 71.3 mmol) was added to dibromoethane
(3.0 g, 15.9 mmol) in acetonitrile (35 ml). The stirred suspension was
treated with 2,2-dimethylpropane-1,3-diamine (excess) and stirred at
room temperature for 24 h. Contents were filtered, filtrate evaporated
and residue distilled under reduced pressure to yield colorless liquid 1
(2.73 g, 11.9 mmol, 74.3%); bp 120–125°C/0.5 mm Hg; 1H NMR
(300 MHz, CDCl3) δ: 0.80 (s, 12H), 1.18 (bs, 6H), 2.38 (m, 4H), 2.50
(m, 4H), 2.64 (m, 4H); 13C NMR (75.4 MHz, CDCl3) δ: 23.5, 35.2,
49.7, 51.2, 58.3.
2-hydroxy-5-ethoxy-benzaldehyde (3)
4-Ethoxyphenol (1.28 g, 9.26 mmol) and trioctylamine (1.64 g,
4.63 mmol) dissolved in toluene (20 ml) were treated with dropwise
addition of tin tetrachloride (1.85 ml, 1.0 M) and stirred for 30 min at
room temperature. Paraformaldehyde (0.83 g, 27.8 mmol) was added
and refluxed at 90°C for 10 h. The contents were cooled to room tem-
perature, hydrolyzed and acidified to pH 2.5, extracted with methylene
chloride (3 × 100 ml), dried over anhydrous sodium sulfate, filtered,
evaporated, and the residue purified on silica using 1% ethylacetate in
hexane. Further evaporation of eluent yielded colorless crystals 3
(0.90 g, 5.42 mmol, 58.5%); mp 52–53°C; 1H NMR (300 MHz, CDCl3)
δ: 1.42 (t, 3H), 4.02 (q, 2H), 6.92 (d, 1H), 6.99 (d, 1H), 7.14 (dd, 1H),
9.84 (s, 1H), 10.65 (s, 1H); 13C NMR (75.4 MHz, CDCl3) δ: 14.6,
64.2, 116.1, 118.6, 120.1, 125.8, 152.1, 156.0, 196.4.
2-(2-hydroxy-3-ethoxyphenyl)-1,3-bis[4-aza-5-(2′-hydroxy-3′-
ethoxyphenyl)2′′,2′′′-dimethyl-but-4′-ene-1′-yl]-1,3-imidazolidine
(H33-Eabi; 4)
Compound 4 was prepared using methods described previously
[27,29]. 1H NMR (300 MHz, CDCl3) δ: 0.81 (s, 6H), 0.83 (s, 6H), 1.40
(t, 3H), 1.49 (t, 6H), 2.28 (d, 2H), 2.55 (d, 2H), 2.69 (m, 2H), 3.05 (d,
2H), 3.40 (d, 2H), 3.52 (d, 2H), 3.78 (s, 1H), 4.05 (q, 2H), 4.09 (q,
4H), 7.10 (m, 2H), 7.20-7.80 (m, 7H), 8.06 (s, 2H) ; 13C NMR (75.4
MHz, CDCl3) δ: 14.6, 14.7, 24.2, 24.4, 36.3, 54.2, 62.2, 64.1, 64.7,
67.3, 91.3, 114.7, 115.4, 117.3, 118.1, 118.4, 122.8, 123.7, 147.1,
147.8, 148.2, 152.8, 165.3, 165.4.
2-(2-hydroxy-5-ethoxyphenyl)-1,3-bis[4-aza-5-(2′-hydroxy-5′-
ethoxyphenyl)2′′,2′′′-dimethyl-but-4′-ene-1′-yl]-1,3-imidazolidine
(H35-Eabi; 5)
Compound 5 was prepared using the methods described previously
[27,29]. 1H NMR (300 MHz, CDCl3) δ: 0.82 (s, 6H), 0.84 (s, 6H), 1.34
(t, 3H), 1.40 (t, 6H), 2.26 (d, 2H), 2.58 (d, 2H), 2.66 (m, 2H), 3.08 (d,
2H), 3.40 (d, 2H), 3.58 (m, 2H), 3.70 (s, 1H), 3.82 (q, 2H), 4.0 (q, 4H),
6.60 (d, 1H), 6.70 (d, 2H), 6.78-7.00 (m, 6H), 8.05 (s, 2H); 13C NMR
(75.4 MHz, CDCl3) δ: 14.7, 14.9, 24.4, 24.6, 36.3, 54.3, 54.6, 62.3,
64.1, 68.0, 91.8, 115.8, 116.8, 117.4, 117.7, 118.4, 119.7, 123.1,
151.1, 151.5, 154.7, 155.3, 164.9, 165.1.
[(3-ethoxy-ENBDMPI)Ga]+ ClO4– (6)
Using the procedure described previously [27,29], H33-Eabi (4;
0.14 g, 0.21 mmol), gallium(III)acetylacetonate (0.08 g, 0.21 mmol),
and potassium perchlorate (0.03 g, 0.21 mmol) were reacted in
methanol. Pale yellow needles were washed with methanol, then ether
and dried to yield 6 (0.10 g, 0.14 mmol, 67.6%); mp 190–192°C dec;
1H NMR (300 MHz, DMSO-d6) δ: 0.90 (s, 6H), 0.95 (s, 6H), 1.40 (t,
6H), 2.60 (m, 2H), 2.70–2.98 (m, 6H), 3.60 (dd, 2H), 3.78 (t, 2H),
4.02 (q, 4H), 4.90 (bs, 2H), 6.60 (t, 2H), 6.88 (dd, 2H), 7.02 (d, 2H),
8.19 (s, 2H); 13C NMR (75.4 MHz, CDCl3) δ: 14.8, 21.9, 26.1, 35.5,
47.6, 59.0, 63.2, 68.9, 115.9, 116.2, 118.8, 125.3, 150.4, 157.2,
170.5; MS(FAB) for [C30H44N4O4Ga]+ m/z = 594.1; κ (Ω–1mol–1cm2)
120; Anal. calcd. for C30H44N4O8GaCl.CH3OH: C, 51.29; H, 6.66; N,
7.72; found: C, 50.99; H, 6.78; N, 7.52. 
[(5-ethoxy-ENBDMPI)Ga]+I– (7)
Using the procedure described previously [27,29], H35-Eabi (5; 59 mg,
0.09 mmol), gallium(III)acetylacetonate (0.03 g, 0.09 mmol), and potas-
sium iodide (14 mg, 0.09 mmol) were reacted in methanol. Pale yellow
needles were washed with methanol, then ether and dried to yield 7
(43 mg, 0.06 mmol, 68.6%); mp 185–188°C dec; 1H NMR (300 MHz,
DMSO-d6) δ: 0.77 (s, 6H), 0.93 (s, 6H), 1.28 (t, 6H), 2.61–2.82 (m,
6H), 2.88 (m, 2H), 3.28 (d, 2H), 3.79 (d, 2H), 3.90 (q, 4H), 4.82 (bs,
2H), 6.81 (d, 2H), 6.83 (d, 2H), 7.05 (dd, 2H), 8.14 (s, 2H); 13C NMR
(75.4 MHz, CDCl3) δ: 14.3, 21.5, 25.9, 35.1, 47.0, 59.4, 62.9, 68.9,
115.7, 117.7, 122.4, 123.9, 148.5, 160.9, 169.6; MS(FAB) for
[C30H44N4O4Ga]+ m/z = 594.1; κ (Ω–1mol–1cm2) 130; Anal. calc, for
C30H44N4O4GaI.CH3OH: C, 49.42; H, 6.42; N, 7.43; found: C, 49.09 ;
H, 6.70 ; N, 7.34.
X-ray crystallography
Crystal data were collected on a single crystal of 6 (0.7 × 0.3 × 0.2 mm)
obtained from slow diffusion of ethyl ether into a solution of 6 in
methanol, and on a crystal of 7 (0.4 × 0.4 × 0.3 mm) obtained from slow
evaporation of a methanol solution, using a Siemens P4 four-circle dif-
fractometer with graphite monochromated Mo-Kα radiation
(λ = 0.71073 Å) at 173°K. The experimental details and refinement pro-
cedures are separately reported in the Supplementary material section.
Crystallographic tables S1–5 for 6 and 7 containing crystal data and
structure refinement parameters, atomic coordinates and equivalent
isotropic displacement parameters (Å × 103), bond lengths (Å) and
angles (°), anisotropic displacement parameters (Å2 × 103), hydrogen
coordinates (× 104) and isotropic displacement parameters (Å2 × 103)
also are included in the Supplementary material section.
Cell transport assays
Cell culture. Monolayers of human epidermoid carcinoma KB 3-1
cells and the colchicine-selected KB 8-5 derivative cell lines were
grown as described previously [9,41]. Briefly, cells were plated in
100 mm Petri dishes containing seven 25 mm glass coverslips on the
bottom and grown to confluence in DMEM (GIBCO, Grand Island, NY)
supplemented with L-glutamine (1%), penicillin/streptomycin (0.1%),
and heat-inactivated fetal calf serum (10%) in the presence of 0 and 10
ng/ml colchicine, respectively.
Solutions and reagents. Stock solutions of GF120918 (gift of
Glaxo-Wellcome, Research Triangle Park, NC) were prepared in
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dimethyl sulfoxide (DMSO). Final concentration of DMSO in experimen-
tal buffers was <1%, which has been found to have no effect on net
uptake of tracer complexes in cultured cells [42]. All other reagents
were obtained from Sigma Chemical Co. Control solution for transport
experiments was a modified Earle’s balanced salt solution (MEBSS)
containing: 145 mM Na+, 5.4 mM K+, 1.2 mM Ca2+, 0.8 mM Mg2+,
152 mM Cl–, 0.8 mM H2PO4–, 0.8 mM SO42–, 5.6 mM dextrose,
4.0 mM HEPES, and 1% bovine calf serum (vol/vol), pH 7.4 ± 0.05. A
130 mM K+/20 mM Cl– solution was made by equimolar substitution of
potassium methanesulfonate for NaCl as described previously[43].
Transport assays. Coverslips with confluent cells were used for
studies of cell transport and kinetics as described previously [9]. In brief,
cells were removed from culture media and washed for 15–30 s in
MEBSS. Accumulation experiments were initiated by immersing cover-
slips in 60 mm glass Pyrex dishes containing 4 ml loading solution con-
sisting of MEBSS with 1–6 nM [67Ga-complex] (300–900 pmol/mCi;
1–2 µCi/ml). Coverslips with cells were removed at various times, rinsed
3 × in 25 ml ice-cold isotope-free solution for 8 s to clear extracellular
spaces, and placed in 35 mm plastic Petri dishes. Cells were extracted
in 1% sodium dodecylsulfate with 10 mM sodium borate before protein
assay by the method of Lowry et al. [44] using bovine serum albumin as
the protein standard. Aliquots of the loading buffer and stock solutions
also were obtained for standardizing cellular data with extracellular con-
centration of each Ga complex. Cell extracts, stock solutions and extra-
cellular buffer samples were assayed for gamma activity in a well-type
sodium iodide gamma counter (Cobra II, Packard, Meridan, Conn.).
Absolute concentration of total Ga complex in solution was determined
from the activity of stock solutions and specific activity of 67Ga. Data are
reported as fmol Ga complex (mg protein)–1 (nMo)–1 as previously
described, with (nMo)–1 representing total concentration of Ga-complex
in the extracellular buffer [45].
Biodistribution studies 
Vertebrate animal procedures were approved by the appropriate insti-
tutional review committee. Distribution of 67Ga complex in the blood,
liver and brain tissues of parental strain FVB mice (FVB/NTacfBR) and
FVB mdr1a/1b(–/–) gene knockout mice (FVB/TacfBR-[KO]mdr1a-
[KO]mdr1bN7) (Taconic, Germantown, NY) was determined as
described previously [10,46]. 67Ga-complex was diluted in 90:10
saline:ethanol to a final concentration of 20 µCi/ml. Mice were anes-
thetized by metafane inhalation and injected with 2 µCi of radiotracer
via bolus injection through a tail vein. Animals were sacrificed by cervi-
cal dislocation at 5, 15, 60 and 120 min post-injection (n = 2–4 each).
Blood samples were obtained by cardiac puncture and tissues har-
vested rapidly. Gamma activity in organ samples was counted for
1 min, or until two standard deviations of sampling were below 0.5%.
Data are expressed as percent of injected dose per gram of tissue
[(tissue µCi) (injected µCi)–1 (g tissue)–1 × 100]. From biodistribution
time-activity curves, area-under-the-curve (AUC) was calculated using
trapezoidal integration (KaleidaGraph, Synergy Software) and reported
as tissue µCi (injected µCi)–1 (g tissue)–1 × 100 × min. Data are gener-
ally reported as mean ± SEM. Pairs were compared by Student’s t test.
Values of p ≤ 0.05 were considered significant.
Supplementary material
Supplementary material including details of crystallographic conditions
is available at http://current-biology.com/supmat/supmatin.htm.
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